Payment overview · 2025
General Payments
$84.88
4 reported records · 3 companies
Healthcare provider profile · identity verified
Jay W Porter, DO
Allopathic & Osteopathic Physicians|Family Medicine · HERMITAGE, PA · NPI 1699745299
Verified facts
What the public records show
CMS Open Payments records show Jay W Porter, DO received $84.88 in general payments during 2025 across 4 reported records.
Novo Nordisk Inc accounted for 55.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $46.70 | 55.0% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.29 | 22.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.89 | 22.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $84.88 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $46.70 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $46.70 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.29 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 78 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
121 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
78 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 635 | 124 |
| Amlodipine Besylate | Amlodipine Besylate | 578 | 119 |
| Atorvastatin Calcium | Atorvastatin Calcium | 564 | 125 |
| Potassium Chloride | Potassium Chloride | 467 | 91 |
| Lisinopril | Lisinopril | 456 | 111 |
| Pantoprazole Sodium | Pantoprazole Sodium | 449 | 85 |
| Metformin Hcl | Metformin Hcl | 391 | 94 |
| Sertraline Hcl | Sertraline Hcl | 386 | 65 |
| Omeprazole | Omeprazole | 381 | 77 |
| Losartan Potassium | Losartan Potassium | 329 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 328 | 83 |
| Pravastatin Sodium | Pravastatin Sodium | 294 | 61 |
| Metoprolol Tartrate | Metoprolol Tartrate | 283 | 57 |
| Gabapentin | Gabapentin | 223 | 40 |
| Furosemide | Furosemide | 185 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 181 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 179 | 46 |
| Glipizide | Glipizide | 175 | 40 |
| Eliquis | Apixaban | 173 | 31 |
| Carvedilol | Carvedilol | 160 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 137 | 33 |
| Januvia | Sitagliptin Phosphate | 137 | 21 |
| Simvastatin | Simvastatin | 127 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 124 | 29 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 124 | 18 |
| Synthroid | Levothyroxine Sodium | 121 | 29 |
| Alprazolam | Alprazolam | 112 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 112 | 29 |
| Glipizide Er | Glipizide | 112 | 22 |
| Allopurinol | Allopurinol | 107 | 29 |
| Atenolol | Atenolol | 103 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 92 | 25 |
| Meloxicam | Meloxicam | 83 | 19 |
| Warfarin Sodium | Warfarin Sodium | 81 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 79 | 62 |
| Doxycycline Hyclate | Doxycycline Hyclate | 79 | 63 |
| Jardiance | Empagliflozin | 79 | 17 |
| Memantine Hcl | Memantine Hcl | 79 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 78 | 18 |
| Ozempic | Semaglutide | 78 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 74 | 29 |
| Farxiga | Dapagliflozin Propanediol | 74 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 72 | 22 |
| Famotidine | Famotidine | 71 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 71 | 15 |
| Methylprednisolone | Methylprednisolone | 70 | 56 |
| Amoxicillin | Amoxicillin | 69 | 60 |
| Clonidine Hcl | Clonidine Hcl | 68 | 11 |
| Ezetimibe | Ezetimibe | 68 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 66 | 14 |
| Tramadol Hcl | Tramadol Hcl | 65 | 16 |
| Azithromycin | Azithromycin | 62 | 48 |
| Alendronate Sodium | Alendronate Sodium | 61 | 12 |
| Montelukast Sodium | Montelukast Sodium | 60 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 54 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 52 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 52 | 28 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 51 | 13 |
| Bupropion Xl | Bupropion Hcl | 49 | suppressed |
| Ursodiol | Ursodiol | 48 | suppressed |
| Finasteride | Finasteride | 47 | suppressed |
| Ibuprofen | Ibuprofen | 47 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 47 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 12 |
| Risperidone | Risperidone | 45 | suppressed |
| Xarelto | Rivaroxaban | 45 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 43 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 43 | 13 |
| Irbesartan | Irbesartan | 42 | suppressed |
| Repaglinide | Repaglinide | 42 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 41 | 15 |
| Buspirone Hcl | Buspirone Hcl | 40 | 11 |
| Benazepril Hcl | Benazepril Hcl | 39 | 11 |
| Trazodone Hcl | Trazodone Hcl | 38 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 36 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Lorazepam | Lorazepam | 33 | 14 |
| Mupirocin | Mupirocin | 31 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Ramipril | Ramipril | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 22 |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 13 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 23 | suppressed |
| Fluconazole | Fluconazole | 22 | 14 |
| Folic Acid | Folic Acid | 22 | suppressed |
| Nystatin | Nystatin | 22 | 11 |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 19 | 14 |
| Clindamycin Phosphate | Clindamycin Phosphate | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Prednisone | Prednisone | 19 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Nateglinide | Nateglinide | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Nexium | Esomeprazole Magnesium | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $84.88 · 4 records | Novo Nordisk Inc | Kerendia, Ozempic, Rybelsus, UBRELVY | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error